Monitor for a prospectus supplement or takedown under the shelf, which would signal an imminent capital raise. The combination of activist presence (Celadon), negative equity, and a pending merger makes any offering highly dilutive. Watch for the effective date of the S-3 and subsequent 424B filings.
Price Chart
Executive Summary
Senti Biosciences filed Amendment No. 3 to its S-3 shelf registration (File No. 333-296917) as an exhibits-only filing to include an updated auditor consent from KPMG LLP. The filing does not change the registration statement's substance, but the active shelf, combined with a recent SC 13D/A from Celadon Partners (activist holder of convertible notes) and a pending merger agreement, signals potential near-term equity issuance or conversion. The company's June 2026 10-Q shows negative shareholders' equity and a going-concern risk, making this shelf a critical capital-access tool.
Key Facts
- Amendment No. 3 to S-3 shelf registration filed on September 22, 2026, adding only an updated KPMG auditor consent.
- The S-3 shelf (File No. 333-296917) was initially filed June 18, 2026, and remains available for future securities offerings.
- Cross-filing context: SC 13D/A filed September 11, 2026, by Celadon Partners SPV 24, an activist holder of senior secured convertible notes.
- Cross-filing context: 10-Q for period ending June 30, 2026, shows accumulated deficit of $[not provided] and negative working capital, indicating financial distress.
- The company has a pending merger agreement (July 14, 2026) and an equity commitment letter from CPIF II-9 Limited (September 3, 2026).
- The shelf registration could enable dilutive equity or convertible offerings to fund operations and merger-related obligations.
Financial Impact
Shelf registration of up to $[undisclosed] in securities; potential dilution from future offerings could be substantial given negative equity base.
Risk Factors
- Potential dilutive equity or convertible offering under the shelf could significantly reduce existing shareholder value.
- Activist holder Celadon Partners may force a conversion of notes or push for a dilutive restructuring.
- Negative shareholders' equity and going-concern risk increase the likelihood of a distressed capital raise.
- Pending merger may require additional financing, increasing the probability of a shelf takedown.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3/A Filing (Primary) | 0001193125-26-397190 |
| Document: d87527dex231.htm | 0001193125-26-397190 |
| Document: 0001193125-26-397190-index-headers.html | 0001193125-26-397190 |
| Document: 0001193125-26-397190-index.html | 0001193125-26-397190 |
| Document: 0001193125-26-397190.txt | 0001193125-26-397190 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $0.1720 | awaiting T+5 | — | $0.1783 (−3.66%) |
Oct 13, 2026 13d ago | DEFA14A | $0.2408 $0.2175 | ▼ −9.68% | ▼ −10.13% | $0.1783 (−25.96%) |
Oct 13, 2026 13d ago | 8-K | $0.2408 $0.2175 | ▲ +9.68% | ▲ +10.13% | $0.1783 (+25.96%) |
Sep 25, 2026 4w ago | EFFECT | $0.3293 $0.3223 | ▲ +2.13% | ▲ +1.90% | $0.1783 (+45.85%) |
Sep 24, 2026 4w ago | DEFM14A | $0.3293 $0.3223 | ▲ +2.13% | ▲ +1.90% | $0.1783 (+45.85%) |
Sep 22, 2026 5w ago | S-3/A | $0.3156 $0.3075 | ▲ +2.57% | ▲ +1.38% | $0.1783 (+43.50%) |
Sep 10, 2026 6w ago | S-3/A | $0.3060 $0.3200 | ▼ −4.58% | ▼ −4.80% | $0.1783 (+41.73%) |
Sep 4, 2026 7w ago | DEFA14A | $0.3326 $0.3021 | ▼ −9.17% | ▼ −7.96% | $0.1783 (−46.39%) |
Sep 4, 2026 7w ago | 8-K | $0.3326 $0.3021 | ▲ +9.17% | ▲ +7.96% | $0.1783 (+46.39%) |
Aug 20, 2026 9w ago | 8-K | $0.3886 $0.3770 | ▲ +2.99% | ▲ +3.46% | $0.1783 (+54.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers